Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Latest Biotechnology and Nurix Therapeutics, Inc., Ionis Pharmaceuticals, Inc. Stock News

As of July 10, 2026, Nurix Therapeutics, Inc. had a $2.4 billion market capitalization, compared to the Biotechnology median of $281.9 million. Nurix Therapeutics, Inc.’s stock is up 19.7% in 2026, down 5.5% in the previous five trading days and up 74.96% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $71.8 million with a -411.4% net profit margin. Year-over-year quarterly sales growth most recently was -65.9%. Analysts expect adjusted earnings to reach $-2.713 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

As of July 10, 2026, Ionis Pharmaceuticals, Inc. had a $9.6 billion market cap, putting it in the 77th percentile of all stocks. Ionis Pharmaceuticals, Inc.’s stock is down 28.3% in 2026, down 31.8% in the previous five trading days and up 36% in the past year.

Currently, Ionis Pharmaceuticals, Inc. does not have a price-earnings ratio. Ionis Pharmaceuticals, Inc.’s trailing 12-month revenue is $1.1 billion with a -30.9% net profit margin. Year-over-year quarterly sales growth most recently was 87.0%. Analysts expect adjusted earnings to reach $-2.614 per share for the current fiscal year. Ionis Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Nurix Therapeutics, Inc.	NRIX	F
Ionis Pharmaceuticals, Inc.	IONS	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Nurix Therapeutics, Inc. has a Value Score of 4, which is Ultra Expensive. Ionis Pharmaceuticals, Inc. has a Value Score of 6, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. is the better investment when it comes to value.

Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Nurix Therapeutics, Inc.	NRIX	F
Ionis Pharmaceuticals, Inc.	IONS	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Nurix Therapeutics, Inc. has a Quality Score of 6, which is Very Weak. Ionis Pharmaceuticals, Inc. has a Quality Score of 5, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. is the better investment when it comes to quality.

Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Nurix Therapeutics, Inc.	NRIX	D
Ionis Pharmaceuticals, Inc.	IONS	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Nurix Therapeutics, Inc. has a Earnings Estimate Score of 31, which is Negative. Ionis Pharmaceuticals, Inc. has a Earnings Estimate Score of 54, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Nurix Therapeutics, Inc., Ionis Pharmaceuticals or Inc. Stock?

Overall, Nurix Therapeutics, Inc. stock has a Value Score of 4, Estimate Revisions Score of 31 and Quality Score of 6.

Ionis Pharmaceuticals, Inc. stock has a Value Score of 6, Estimate Revisions Score of 54 and Quality Score of 5.

Comparing Nurix Therapeutics, Inc., Ionis Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.